Advantage of adjunct metformin and insulin therapy in the management of glycemia in critically ill patients. Evidence for nonoccurrence of lactic acidosis and needing to parenteral metformin

Archives of Medical Science

Volumn 4, Issue 2, 2008, Pages 174-181

  Mojtahedzadeh, Mojtaba ^a   Rouini, Mohammad R ^a   Kajbaf, Farshad ^a   Najafi, Atabak ^b   Ansari, Ghazal ^a   Gholipour, Afshin ^b   Mofid, Ali R ^b   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Critically ill patients; Insulin resistance; Insulin sensitizing agents; Intensive insulin therapy; Metformin; Stress induced hyperglycemia

Indexed keywords

GLUCOSE; INSULIN; LACTIC ACID; METFORMIN;

ACID BASE BALANCE; ADJUVANT THERAPY; ADULT; APACHE; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNIVERSITY HOSPITAL; VOMITING;

EID: 48249150294     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Mizock BA. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Pract Res Clin Endocrinol Metab 2001; 15: 533-51.
2. Beishuizen A, Thijs LG. The immunoneuroendocrine axis in critical illness: beneficial adaptation or neuroendocrine exhaustion? Curr Opin Crit Care 2004; 10: 461-7.
3. Robertson CM, Coopersmith CM. The systemic inflammatory response syndrome. Microbes Infect 2006; 8: 1382-9.
4. Kajbaf F, Mojtahedzadeh M, Abdollahi M. Mechanisms underlying stress-induced hyperglycemia in critically ill patients. Therapy 2007; 4: 97-106.
5. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-67.
6. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004; 79: 992-1000.
7. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest 2004; 114: 1187-95.
8. Brown G, Dodek P. Intravenous insulin nomogram improves blood glucose control in the critically ill. Crit Care Med 2001; 29: 1714-9.
9. Van den Berghe G, Wilmer A, Milants I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes 2006; 55: 3151-9.
10. Gennari FJ. Hypokalemia. N Engl J Med 1998; 339: 451-8.
11. Delva P, Degan M, Trettene M, Lechi A. Insulin and glucose mediate opposite intracellular ionized magnesium variations in human lymphocytes. J Endocrinol 2006; 190: 711-8.
12. Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993; 21: 1024-9.
13. Huerta MG, Roemmich JN, Kington ML, et al. Magnesium deficiency is associated with insulin resistance in obese children. Diabetes Care 2005; 28: 1175-81.
14. Choi CS, Thompson CB, Leong PK, McDonough AA, Youn JH. Short-term K(+) deprivation provokes insulin resistance of cellular K(+) uptake revealed with the K(+) clamp. Am J Physiol Renal Physiol 2001; 280: F95-F102.
15. ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control: a call to action. Diabetes Care 2006; 29: 1955-62.
16. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411.
17. Wiholm BE, Myrhed M. Metformin-associated lactic acidosis 1977-1991. Eur J Clin Pharmacol 1993; 44: 589-91.
18. Lalau JD, Race JM. Lactic acidosis in metformin therapy. Drugs 1999; 58 (Suppl. 1): 55-60.
19. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004; 255: 179-87.
20. Gore DC, Wolf SE, Herndon DN, Wolfe RR. Metformin blunts stress-induced hyperglycemia after thermal injury. J Trauma 2003; 54: 555-61.
21. Gore DC, Herndon DN, Wolfe RR. Comparison of peripheral metabolic effects of insulin and metformin following severe burn injury. J Trauma 2005; 59: 316-22.
22. Guidance for Industry: Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), May 2001. http://www.fda.gov/cder/guidance.
23. Amini H, Ahmadiani A, Gazerani P. Determination of metformin in human plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 824: 319-22.
24. Zarghi A, Foroutan SM, Shafaati A, Khoddam A. Rapid determination of metformin in human plasma using ion-pair HPLC. J Pharm Biomed Anal 2003; 31: 197-200.
25. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
26. Caballero AE, Delgado A, Aguilar-Salinas CA, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2004; 89: 3943-8.
27. Malmberg K, Rydén L, Wedel H, et al.; DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650-61.
28. Mehta SR, Yusuf S, Diaz R, et al.; CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005; 293: 437-46.
29. Vanhorebeek I, Langouche L, Van den Berghe G. Glycemic and nonglycemic effects of insulin: how do they contribute to a better outcome of critical illness? Curr Opin Crit Care 2005; 11: 304-11.
30. Andreelli F, Jacquier D, Troy S. Molecular aspects of insulin therapy in critically ill patients. Curr Opin Clin Nutr Metab Care 2006; 9: 124-30.
31. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 2003; 31: 359-66.
32. Hadidi E, Mojtahedzadeh M, Paknejad MH, et al. Alterations of blood IL-8, TGF-beta1 and nitric oxide levels in relation to blood cells in patients with acute brain injury. Therapy 2006; 3: 413-9.
33. Salari P, Mojtahedzadeh M, Najafi A, et al. Comparison of the effect of aminophylline and low PEEP vs. high PEEP on EGF concentration in critically ill patients with ALI/ARDS. J Clin Pharm Ther 2005; 30: 139-44.
34. Dandona P, Mohanty P, Chaudhuri A, Garg R, Aljada A. Insulin infusion in acute illness. J Clin Invest 2005; 115: 2069-72.
35. Robinson LE, van Soeren MH. Insulin resistance and hyperglycemia in critical illness: role of insulin in glycemic control. AACN Clin Issues 2004; 5: 45-62.
36. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33.
37. Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006; 47: 1183-8.
38. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother 2005; 59: 365-73.
39. Soltan-Sharifi MS, Mojtahedzadeh M, Najafi A, et al. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and antioxidant power: evidence for underlying toxicological mechanisms. Hum Exp Toxicol 2007; 26: 697-703.
40. Larijani B, Afshari M, Astanehi-Asghari F, et al. Effect of short-term carvedilol therapy on salivary and plasma oxidative stress parameters and plasma glucose level in type II diabetes. Therapy 2006; 3: 119-23.
41. Vazin A, Mojtahedzadeh M, Najafi A, Khalilzadeh A, Abdollahi M. Relationship between duration, fatality rate and severity of disease and serum epidermal growth factor in human acute lung injury. Therapy 2005; 2: 255-9.
42. Salari P, Mojtahedzadeh M, Abdollahi M. Influence of serum epidermal growth factor on mechanical ventilation and survival in patients with acute respiratory distress syndrome. Therapy 2005; 2: 393-8.
43. Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdollahi M. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother 2005; 59: 302-6.
44. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30: 359-71.
45. Power BM, Forbes AM, van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998; 34: 25-56.
46. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006; 22: 255-71.
47. Marchetti P, Giannarelli R, di Carlo A, Navatesi R. Pharmacokinetic optimisation of oral hypoglycaemic therapy. Clin Pharmacokinet 1991; 21: 308-17.
48. Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med 2006; 166: 1975-9.
49. Clement S, Braithwaite SS, Magee MF, et al; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27: 553-91.
50. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348: 607-14.
51. Valenza F, Aletti G, Fossali T, et al. Lactate as a marker of energy failure in critically ill patients: hypothesis. Crit Care 2005; 9: 588-93.
52. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003; 163: 2594-602.
53. Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'. Diabetes Obes Metab 2001; 3: 195-201.
54. Lalau JD, Mourlhon C, Bergeret A, Lacroix C. Consequences of metformin intoxication. Diabetes Care 1998; 21: 2036-7.
55. Sum CF, Webster JM, Johnson AB, Catalano C, Cooper BG, Taylor R. The effect of intravenous metformin on glucose metabolism during hyperglycemia in type 2 diabetes. Diabet Med 1992; 9: 61-5.
56. Iannello S, Camuto M, Cavaleri A, et al. Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids. Diabetes Obes Metab 2004; 6: 8-15.
57. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-74.
58. Bayrak A, Terbell H, Urwitz-Lane R, Mor E, Stanczyk FZ, Paulson RJ. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertil Steril 2007; 87: 870-5.
59. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-8.
60. Mojtahedzadeh M, Vazin A, Najafi A, Khalilzadeh A, Abdollahi M. The effect of furosemide infusion on serum epidermal growth factor concentration after acute lung injury. J Infus Nurs 2005; 28: 188-93.
61. Hadidi E, Mojtahedzadeh M, Rouini MR, et al. The evaluation of the possible effect of positive end expiratory pressure (PEEP) on pharmacokinetics of phenytoin in patients with acute brain injury under mechanical ventilation. DARU 2005; 13: 74-81.